Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

UCA1 copy number gain in serum cfDNA predicts next-generation antiandrogen resistance in metastatic castration-resistant prostate cancer.

Scientific reports·2026
Same author

Pan-cancer multi-omic integration of Trop2 reveals biological determinants and translational implications for ADC therapy.

NPJ precision oncology·2026
Same author

Site-dependent treg cell transcriptional reprograming in a metastatic colorectal cancer model holds prognostic significance.

Cancer letters·2026
Same author

All screens lead to polo-like kinase 1: A central node in cancer therapeutics and resistance.

Pharmacological research·2026
Same author

Functional germline variants together with somatic mutations alter the integrity of cancer hallmark regulatory networks.

Genome medicine·2026
Same author

Overweight and obesity increase breast cancer risk in postmenopausal women: a meta-analysis of 38 observational studies.

GeroScience·2026
Same journal

Beyond EML4: efficacy of targeted therapy in lung cancer patients with rare ALK fusions - a real-world retrospective analysis.

NPJ precision oncology·2026
Same journal

GLP-1 receptor agonist targets an AMPKα1-HIF1α-PFKFB3 metabolic vulnerability and enhances Lenvatinib response in hepatocellular carcinoma.

NPJ precision oncology·2026
Same journal

Redefining therapeutic horizons in thymic epithelial tumors: precision, combinations, and emerging biology.

NPJ precision oncology·2026
Same journal

Cell-free DNA dynamics and progression-free survival in metastatic gastroesophageal adenocarcinoma: insights from the REGIRI-PRODIGE 58 ancillary study.

NPJ precision oncology·2026
Same journal

OncoGen.AI: an integrated platform for automated genomic analysis and reporting in precision oncology.

NPJ precision oncology·2026
Same journal

Deep learning-driven MRI radiomics reveals biological subtypes and predicts recurrence risk in rectal cancer.

NPJ precision oncology·2026
See all related articles

Related Experiment Video

Updated: Jun 9, 2025

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.0K

Development and validation of a gene expression-based Breast Cancer Purity Score.

Marco Barreca1,2, Matteo Dugo3, Barbara Galbardi3

  • 1Department of Biotechnology and Biosciences, University of Milano-Bicocca, Milan, Italy.

NPJ Precision Oncology
|October 25, 2024
PubMed
Summary
This summary is machine-generated.

A new 9-gene Breast Cancer Purity Score (BCPS) accurately estimates tumor purity in breast cancer samples. This score helps reduce bias in molecular data analysis and improves cancer prognostication and treatment response prediction.

More Related Videos

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

8.9K
Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells
16:24

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells

Published on: February 21, 2014

20.2K

Related Experiment Videos

Last Updated: Jun 9, 2025

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.0K
Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

8.9K
Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells
16:24

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells

Published on: February 21, 2014

20.2K

Area of Science:

  • Oncology
  • Genomics
  • Bioinformatics

Background:

  • Tumor purity, the proportion of malignant cells, influences molecular profiling of bulk samples.
  • Variability in tumor purity introduces bias in data analysis and interpretation.
  • Existing methods for estimating tumor purity lack breast cancer specificity.

Purpose of the Study:

  • To develop and validate a novel, breast cancer-specific method for estimating tumor purity.
  • To assess the performance of the new method against existing techniques.
  • To evaluate the utility of the new score in improving molecular data interpretation and clinical prognostication.

Main Methods:

  • Interrogation of over 6000 expression profiles from 10 diverse breast cancer datasets.
  • Development and validation of a 9-gene Breast Cancer Purity Score (BCPS).
  • Comparative analysis of BCPS against existing tumor purity estimation methods.

Main Results:

  • The developed BCPS demonstrated superior performance in estimating tumor content compared to existing methods.
  • Adjusting transcriptomic profiles with BCPS effectively reduced sampling bias and aided data interpretation.
  • BCPS-estimated tumor purity showed improved prognostication in luminal breast cancer.
  • BCPS correlated with pathologic complete response in triple-negative breast cancer patients.
  • BCPS stratified relapse risk in HER2+ residual disease post-neoadjuvant treatment.

Conclusions:

  • The 9-gene BCPS is a robust and accurate tool for estimating tumor purity in breast cancer.
  • BCPS facilitates more reliable molecular data analysis and interpretation in large clinical cohorts.
  • Application of BCPS enhances clinical prognostication and prediction of treatment outcomes in various breast cancer subtypes.